Billion

Gains

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div>
<p class="has-drop-cap">In a volatile day of trading, three major players in the automotive and biotech sectors are making headlines. Tesla (<a href="https://tokenist.com/investing/how-to-buy-stocks/" rel="noopener noreferrer nofollow" class="deco-link">NASDAQ: TSLA</a>), Rivian (<a href="https://tokenist.com/investing/how-to-buy-shares-online/" class="deco-link" rel="noopener noreferrer nofollow">NASDAQ: RIVN</a>), and Moderna (<a href="https://tokenist.com/investing/how-to-invest-in-stocks/" class="deco-link" rel="noopener noreferrer nofollow">NYSE: MRNA</a>) are each experiencing significant stock movements driven by analyst updates, strategic partnerships, and vaccine efficacy data. Here’s a closer look at the latest developments for these closely watched stocks.</p>
<h3 id="tesla-tsla-stock-gains-as-stifel-nicolaus-initiates-coverage-with-buy-rating-price-target-of-265">Tesla (TSLA) Stock Gains as Stifel Nicolaus Initiates Coverage with “Buy” Rating, Price Target of $265</h3>
<p>Tesla’s stock is rising, gaining 4.26% to reach $195.34 per share as of 11:58 AM EDT. The surge comes as Stifel Nicolaus <a href="https://www.investors.com/news/tesla-stock-buy-point-analyst-bullish/" target="_blank" aria-label="initiated coverage (opens in a new tab)" rel="noopener noreferrer nofollow" class="deco-link">initiated coverage</a> on the electric vehicle maker with a “buy” rating and a price target of $265.00, well above the current trading price. <br><br>This positive outlook contrasts with the overall analyst consensus, which maintains a “Hold” rating and a more conservative price target of $187.30.</p>
<p>Despite the day’s gains, Tesla’s year-to-date performance remains negative, down 21.46% and underperforming <a href="https://tokenist.com/investing/spx-vs-spy/" rel="noopener noreferrer nofollow" class="deco-link">the S&amp;P 500</a>. <br><br>The company recently reported quarterly earnings of $0.35 per share, meeting estimates, though revenue of $21.30 billion fell short of expectations. With a market capitalization of $622.404 billion and a <a href="https://tokenist.com/investing/p-e-ratio/" class="deco-link" rel="noopener noreferrer nofollow">P/E ratio</a> of 47.94, Tesla remains dominant in the EV market despite increasing competition.</p>
<div class="cta-referral"><img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async">
 <div class="cta-referral__text">
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking story.</a></p>
 </div>
</div>
<h3 id="rivian-rivn-gets-a-5-billion-lifeline-from-volkswagen-stock-surges">Rivian (RIVN) Gets a $5 Billion Lifeline from Volkswagen, Stock Surges</h3>
<p>Rivian’s stock is experiencing a dramatic surge, up 26.80% to $15.16 per share, following news of a potential <a href="https://www.nytimes.com/2024/06/25/business/volkswagen-rivian-vw-investment.html" target="_blank" aria-label="$5 billion investment (opens in a new tab)" rel="noopener noreferrer nofollow" class="deco-link">$5 billion investment</a> from Volkswagen. <br><br>The proposed deal would involve forming an equally controlled joint venture to share EV architecture and software, potentially transforming Rivian’s market position and financial outlook.</p>
<p>Analysts are hailing the partnership as a “core game changer” for Rivian. The funding is expected to bolster the company’s cash reserves and support the development of new models, including the R2 SUVs and R3 crossovers. <br><br>However, some analysts caution that the funding could dilute Rivian’s share price. The news has propelled Rivian’s market capitalization to $15.094 billion, though the company still reports negative earnings, with an EPS of -$5.77.</p>
<h3 id="moderna-mrna-stock-faces-downward-pressure-after-release-of-efficacy-data-for-newly-approved-rsv-vaccine">Moderna (MRNA) Stock Faces Downward Pressure After Release of Efficacy Data for Newly Approved RSV Vaccine</h3>
<p>Moderna’s stock is facing downward pressure, declining 5.40% to $130.17 per share, following the <a href="https://seekingalpha.com/news/4119662-moderna-stock-dips-rsv-vaccine-efficacy-data?source=feed_sector_healthcare" target="_blank" aria-label="release of efficacy data (opens in a new tab)" rel="noopener noreferrer nofollow" class="deco-link">release of efficacy data</a> for its newly approved RSV vaccine, mRESVIA. <br><br>The latest data shows 50% vaccine efficacy against two or more lower respiratory tract disease symptoms, which some analysts consider to be on the lower end of expectations.</p>
<p>The FDA approved the vaccine last month for adults 60 and older and is now under review by the CDC’s Advisory Committee on Immunization Practices (ACIP). <br><br>The committee’s opinion will determine the vaccine’s market rollout. Moderna faces stiff competition from GSK and Pfizer, who already have approved RSV vaccines. Despite the day’s losses, Moderna’s year-to-date return remains positive at 30.89%, outperforming the S&amp;P 500.</p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe>
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em></p>
<h3 id="br"><br></h3>
<p>The post <a rel="noopener noreferrer nofollow" href="https://tokenist.com/stocks-to-watch-today-tsla-rivn-and-moderna/">Stocks to Watch Today: TSLA, RIVN, and Moderna</a> appeared first on <a rel="noopener noreferrer nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Stocks to Watch Today: TSLA, RIVN, and Moderna

Mục lục

Tokenist

Các bài viết khác được xuất bản trên 26 thg 6, 2024

Shiba Inu Price Predictions: Mpeppe (MPEPE) Set To Dominate 2024 Market By 1000%

Binance’s Dubai unit wins VASP license

W3Expo — The Original In-Person Web3 Gaming Expo — Returns for Istanbul Blockchain Week 2024

Why Are Memecoins Declining?

BitDoge Meme Coin Launches Presale On Bitcoin Network

After a stunning victory over Portugal, the Georgian national team advanced to the quarterfinals ...

Tham gia bản tin miễn phí của chúng tôi để cập nhật tin tức về tiền điện tử hàng ngày!